ReviewPharmacoEconomics2019

Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Sabine E Grimm et al.PubMed ↗Publisher ↗

No numbers read from the abstract.